Liz Szabo
Kaiser Health News
As an emergency physician, Dr. Eugenia South was in the first group of people to receive a COVID-19 vaccine. She received her second dose last week – even before President-elect Joe Biden.
Yet South said she’s in no rush to throw away her face mask.
“I honestly don’t think I’ll ever go without a mask at work again,” said South, faculty director of the Urban Health Lab at the University of Pennsylvania in Philadelphia. “I don’t think I’ll ever feel safe doing that.”
And although vaccines are highly effective, South plans to continue wearing her mask outside the hospital as well.
New coronavirus variant could take over by spring, experts say
Proactive testing, faster vaccinations and strict adherence to health guidelines are needed to prevent new surges, say scientists.
A nurse holds a vial of the Pfizer-BioNTech COVID-19 vaccine at a hospital in London. Company executives say they are confident the vaccine works against the UK variant of the virus, but further studies are needed to be completely sure.(Frank Augstein / AP)
A more contagious variant of COVID-19 first detected in England has hit North Texas just as hospitals are being stretched to the limit. Even as vaccines roll out in Dallas-Fort Worth, experts worry they aren’t reaching people fast enough to stay ahead of the variant, which they fear will trigger a new surge.
News Category Global Banking & Finance Reviews
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer
Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy
Safety Profile Continues to be Favorable
EDINBURGH, United Kingdom, Jan. 15, 2021 NuCana plc (NASDAQ: NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.
NuTide:302 is a three-part study investigating NUC-3373, NuCana’s targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373’s optimal dose and schedule in combination with agents commonly used to treat patients with co
Researchers from The Ohio State University believe that it may be possible to reduce these negative effects using simple measures such as exercise and sleep.